DIFFERENTIAL EXPRESSION GENE PROFILES AND APPLICATIONS IN MOLECULAR STAGING OF HUMAN GASTRIC CANCER

• US 20090117561A1
• Filed: 10/13/2005
• Published: 05/07/2009
• Est. Priority Date: 08/02/2005
• Status: Abandoned Application

• Current Assignee: Jing Cheng, Ruifang Guo, Shizhu Zang, Yonghong Ren, Yonglong Zhuang, Youyong Lu, Zhang Liang
• Original Assignee: Jing Cheng, Ruifang Guo, Shizhu Zang, Yonghong Ren, Yonglong Zhuang, Youyong Lu, Zhang Liang
• Inventors: Zang, Shizhu, Guo, Ruifang, Lu, Youyong, Ren, Yonghong, Zhuang, Yonglong, Zhang, Liang, Cheng, Jing
• Application Number:
  US11/997,313
• Publication Number:
  US 20090117561A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

The invention provides methods for detecting differential gene expression in intestinal gastric tissue in a mammal by comparing the expression of specific genes in an intestinal gastric tissue suspected of being cancerous with that of the corresponding adjacent intestinal gastric tissue or a normal gastric mucosa tissue. The methods can be used in diagnosing or monitoring the progression of intestinal gastric cancer and determining the levels of differentiation of intestinal gastric cancer Systems and kits for methods of the invention are also provided.

Claims

1. A method for diagnosing intestinal gastric cancer in a mammal, comprising:

(a) detecting levels of expression of at least two genes shown in FIG. 1 in an intestinal gastric tissue of the mammal, wherein the tissue is suspected of being cancerous;

(b) detecting levels of expression of the genes in an intestinal gastric tissue adjacent to the tissue suspected of being cancerous of the mammal; and

(c) comparing the levels of expressions of the genes in the tissue suspected of being cancerous to the levels of expression in the adjacent tissue;

wherein substantial variance of the levels of expression of the genes between the tissue suspected of being cancerous and the adjacent tissue is indicative of presence of intestinal gastric cancer in the mammal.

2. The method of claim 1, wherein the levels of expression of all the genes in FIG. 1 are detected, wherein substantially increased expression of at least 18 of genes 72-102 in FIG. 1 and substantially decreased expression of at least 42 of genes 1-71 in FIG. 1 in the tissue suspected of being cancerous as compared to the adjacent tissue are indicative of presence of intestinal gastric cancer in the mammal.

3. The method of claim 1, wherein the levels of expression of all the genes in FIG. 1 are detected, wherein substantially increased expression of genes 72-102 in FIG. 1 and substantially decreased expression of genes 1-71 in FIG. 1 in the tissue suspected of being cancerous as compared to the adjacent tissue are indicative of presence of intestinal gastric cancer in the mammal.

4. The method of claim 1, wherein the levels of expression of the genes are detected by detecting the levels of mRNA encoded by the genes.

5. The method of claim 1, wherein the levels of expression of the genes are detected by detecting the levels of the protein encoded by the genes.

6. A system for diagnosing intestinal gastric cancer in a mammal, consisting essentially of a plurality of isolated polynucleotide molecules, wherein each isolated polynucleotide molecule is capable of detecting expression of a gene selected from the group consisting of at least 61 genes shown in FIG. 1, whereby differential expression of said genes can be detected.

7. The system of claim 6, wherein the isolated polynucleotide molecules are selected from the group consisting of DNA, RNA, and PNA.

8. A kit comprising the system of claim 6.

9. The kit of claim 8, wherein the isolated polynucleotide molecules are immobilized on an array.

10. A method for diagnosing intestinal gastric cancer in a mammal, comprising:

(a) detecting levels of expression of at least two genes shown in FIG. 2 in an intestinal gastric tissue suspected of being cancerous of the mammal;

(b) detecting levels of expression of the genes in an intestinal gastric tissue adjacent to the gastric tissue suspected of being cancerous;

(c) comparing the levels of expression of the genes in the gastric tissue suspected of being cancerous to levels of expression of the genes in a normal intestinal gastric mucosa tissue of the same mammal species;

(d) comparing the levels of expression of the genes in the adjacent gastric tissue to levels of expression of the genes in a normal intestinal gastric mucosa tissue of the same mammal species; and

(e) comparing the levels of expression of the genes in the gastric tissue suspected of being cancerous to the levels of expression of the genes in the adjacent gastric tissue;

wherein substantial variance of the levels of expression of the genes shown in FIG. 2 between the gastric tissue suspected of being cancerous and the normal gastric mucosa tissue and between the adjacent gastric tissue and the normal gastric mucosa tissue, and no substantial variance of the levels of expression of the genes shown in FIG. 2 between the gastric tissue suspected of being cancerous and the adjacent gastric tissue is indicative of presence of intestinal gastric cancer in the mammal.

11. The method of claim 10, wherein the levels of expression of all the genes in FIG. 2 is detected, wherein substantially increased expression of at least 18 of genes 54-84 in FIG. 2 and substantially decreased expression of at least 31 of genes 1-53 in FIG. 2 in the gastric tissue suspected of being cancerous and the adjacent tissue as compared to the normal gastric mucosa tissue are indicative of presence of intestinal gastric cancer in the mammal.

12. The method of claim 10, wherein the levels of expression of all the genes in FIG. 2 is detected, wherein substantially increased expression of genes 54-84 in FIG. 2 and substantially decreased expression of genes 1-53 in FIG. 2 in the gastric tissue suspected of being cancerous and the adjacent tissue as compared to the normal gastric mucosa tissue are indicative of presence of intestinal gastric cancer in the mammal.

13. The method of claim 10, wherein the levels of expression of the genes is detected by detecting the levels of mRNA encoded by the genes.

14. The method of claim 10, wherein the levels of expression of the genes is detected by detecting the levels of the protein encoded by the genes.

15. A system for diagnosing intestinal gastric cancer in a mammal, consisting essentially of a plurality of isolated polynucleotide molecules, wherein each isolated polynucleotide molecule is capable of detecting expression of a gene selected from the group consisting of at least 50 genes shown in FIG. 2, whereby differential expression of said genes can be detected.

16. The system of claim 15, wherein the isolated polynucleotide molecules are selected from the group consisting of DNA, RNA, and PNA.

17. A kit comprising the system of claim 15.

18. The kit of claim 17, wherein the isolated polynucleotide molecules are immobilized on an array.

19. A method for assessing levels of differentiation of intestinal gastric cancer in a mammal, comprising:

(a) detecting levels of expression of at least two genes shown in FIG. 3 in an intestinal gastric cancer tissue of the mammal;

(b) detecting levels of expression of the genes in an intestinal gastric tissue adjacent to the cancer tissue; and

(c) comparing the levels of expression of the genes in the cancer tissue to the levels of expression of the genes in the adjacent tissue;

wherein substantial variance of the levels of expression of the genes between the cancer tissue and the adjacent tissue is indicative of high level of differentiation of the intestinal gastric cancer in the mammal.

20. The method of claim 19, wherein the levels of expression of all the genes in FIG. 3 is detected, wherein substantially increased expression of at least 9 of genes 1-16 in FIG. 3 and substantially decreased expression of at least 23 of genes 17-55 in FIG. 3 in the cancer tissue as compared to the adjacent tissue are indicative of high level of differentiation of the intestinal gastric cancer in the mammal.

21. The method of claim 19, wherein the levels of expression of all the genes in FIG. 3 is detected, wherein substantially increased expression of genes 1-16 in FIG. 3 and substantially decreased expression of genes 17-55 in FIG. 3 in the cancer tissue as compared to the adjacent tissue are indicative of high level of differentiation of the intestinal gastric cancer in the mammal.

22. The method of claim 19, wherein the levels of expression of the gene is detected by detecting the levels of mRNA encoded by the gene.

23. The method of claim 19, wherein the levels of expression of the gene is detected by detecting the levels of the protein encoded by the gene.

24. A system for assessing levels of differentiation of intestinal gastric cancer in a mammal, consisting essentially of a plurality of isolated polynucleotide molecules, wherein each isolated polynucleotide molecule is capable of detecting expression of a gene selected from the group consisting of at least 33 genes shown in FIG. 3, whereby differential expression of said genes can be detected.

25. The system of claim 24, wherein the isolated polynucleotides are selected from the group consisting of DNA, RNA, and PNA.

26. A kit comprising the system of claim 24.

27. The kit of claim 26, wherein the isolated polynucleotides are immobilized on an array.

28. A method for assessing levels of differentiation of intestinal gastric cancer in a mammal, comprising:

(a) detecting levels of expression of at least two genes shown in FIG. 4 in an intestinal gastric cancer tissue of the mammal;

(b) detecting levels of expression of the genes in an intestinal gastric tissue adjacent to the cancer tissue; and

(c) comparing the levels of expression of the genes in the cancer tissue to the levels of expression in the adjacent tissue;

wherein substantial variance of the levels of expression of the genes between the cancer tissue and the adjacent tissue is indicative of low level of differentiation of the intestinal gastric cancer in the mammal.

29. The method of claim 28, wherein the levels of expression of all the genes in FIG. 4 is detected, wherein substantially increased expression of at least 16 of genes 1-28 in FIG. 4 and substantially decreased expression of at least 10 of genes 29-46 in FIG. 4 in the cancer tissue as compared to the adjacent tissue are indicative of low level of differentiation of the intestinal gastric cancer in the mammal.

30. The method of claim 28, wherein the levels of expression of all the genes in FIG. 4 is detected, wherein substantially increased expression of genes 1-28 in FIG. 4 and substantially decreased expression of genes 29-46 in FIG. 4 in the cancer tissue as compared to the adjacent tissue are indicative of high level of differentiation of the intestinal gastric cancer in the mammal.

31. The method of claim 28, wherein the levels of expression of the genes is detected by detecting the levels of mRNA encoded by the genes.

32. The method of claim 28, wherein the levels of expression of the genes is detected by detecting the levels of the protein encoded by the genes.

33. A system for assessing levels of differentiation of intestinal gastric cancer in a mammal, consisting essentially of a plurality of isolated polynucleotide molecules, wherein each isolated polynucleotide molecule is capable of detecting expression of a gene selected from the group consisting of at least 27 genes shown in FIG. 4, whereby differential expression of said genes can be detected.

34. The system of claim 33, wherein the isolated polynucleotides are selected from the group consisting of DNA, RNA, and PNA.

35. A kit comprising the system of claim 33.

36. The kit of claim 35, wherein the isolated polynucleotide molecules are immobilized on an array.